|
Market Cap | 9.18M | EPS (ttm) | -1.64 |
P/E | - | EPS this Y | 52.44% |
Forward P/E | - | EPS next Y | 25.64% |
PEG | - | EPS past 5Y | -55.07% |
P/S | 0.33 | EPS next 5Y | - |
P/B | 38.51 | EPS Q/Q | -121.26% |
Dividend | - | Sales Q/Q | -26.32% |
Insider Own | 71.16% | Inst Own | 4.34% |
Insider Trans | 0.00% | Inst Trans | -12.74% |
Short Float | 1.21% | Earnings | Mar 28/a |
Analyst Recom | 1.67 | Target Price | 4.00 |
Avg Volume | 765.80K | 52W Range | 0.30 - 3.01 |
|
|
|
Telesis Bio, Inc. engages in the provision of automated multi-omic and synthetic biology solutions. The firm also focuses on providing applications to enable researchers to rapidly, accurately, and reproducibly build or write synthetic DNA and mRNA and short oligonucleotides such as CRISPR guides that are ready to use in many downstream synthetic biology enabled markets. The company was founded by Daniel G. Gibson and J. Craig Venter on March 24, 2011 and is headquartered in San Diego, CA. |
|
|
|
Market Cap | 1.54M | EPS (ttm) | -63.58 |
P/E | - | EPS this Y | - |
Forward P/E | - | EPS next Y | - |
PEG | - | EPS past 5Y | 26.64% |
P/S | - | EPS next 5Y | - |
P/B | 1.02 | EPS Q/Q | 87.41% |
Dividend | - | Sales Q/Q | - |
Insider Own | 5.82% | Inst Own | 0.73% |
Insider Trans | 0.00% | Inst Trans | 7.98% |
Short Float | 0.51% | Earnings | Apr 01/b |
Analyst Recom | 1.00 | Target Price | 2520.00 |
Avg Volume | 324.87K | 52W Range | 0.40 - 53.90 |
|
|
|
GRI Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for inflammatory, fibrotic, and autoimmune diseases. It focuses on its lead program, GRI-0621, an inhibitor of type 1 invariant Natural Killer T (iNKT) cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis. The company was founded in May 2009 and is headquartered in La Jolla, CA. |
|
|
|
Market Cap | 4.26M | EPS (ttm) | -1.87 |
P/E | - | EPS this Y | 35.56% |
Forward P/E | - | EPS next Y | 0.34% |
PEG | - | EPS past 5Y | -69.45% |
P/S | - | EPS next 5Y | - |
P/B | - | EPS Q/Q | 54.40% |
Dividend | - | Sales Q/Q | - |
Insider Own | 29.68% | Inst Own | 5.45% |
Insider Trans | 0.45% | Inst Trans | - |
Short Float | 0.30% | Earnings | - |
Analyst Recom | 2.00 | Target Price | 21.00 |
Avg Volume | 57.05K | 52W Range | 0.65 - 11.91 |
|
|
|
Alzamend Neuro, Inc. is an early clinical-stage biopharmaceutical company, which focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which is in Phase II clinical trial, and delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bipolar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders, and AL002, which completed preclinical stage, and uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. The company was founded on February 26, 2016 by Milton C. Ault, III and is headquartered in Atlanta, GA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
AULT MILTON C III | Director | Apr 19 '24 | Buy | 0.69 | 1,000 | 688 | 771,699 | Apr 23 08:00 PM | AULT MILTON C III | Director | Apr 01 '24 | Buy | 0.91 | 334 | 304 | 770,699 | Apr 03 05:00 PM | AULT MILTON C III | Director | Jan 05 '24 | Buy | 1.02 | 5,000 | 5,092 | 768,365 | Jan 09 04:30 PM | AULT MILTON C III | Director | Jan 05 '24 | Buy | 1.06 | 2,000 | 2,127 | 770,365 | Apr 01 04:30 PM | AULT MILTON C III | 10% Owner | Dec 26 '23 | Buy | 0.90 | 500 | 450 | 26,032 | Dec 27 04:30 PM |
|
|
| |
|
Market Cap | 581.47M | EPS (ttm) | - |
P/E | - | EPS this Y | 96.35% |
Forward P/E | - | EPS next Y | -22.14% |
PEG | - | EPS past 5Y | - |
P/S | - | EPS next 5Y | - |
P/B | - | EPS Q/Q | - |
Dividend | - | Sales Q/Q | - |
Insider Own | 29.61% | Inst Own | 6.51% |
Insider Trans | 19.27% | Inst Trans | - |
Short Float | 5.13% | Earnings | Mar 26/a |
Analyst Recom | 1.00 | Target Price | 42.75 |
Avg Volume | 499.93K | 52W Range | 13.75 - 35.06 |
|
|
|
Kyverna Therapeutics, Inc. is a cell therapy clinical-stage biotechnology company. It develops treatments and potential cures for serious autoimmune diseases. The company was founded in June 2018 and is headquartered in Emeryville, CA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
GILEAD SCIENCES, INC. | 10% Owner | Feb 12 '24 | Buy | 22.00 | 910,000 | 20,020,000 | 4,126,119 | Feb 13 05:48 PM | Northpond Ventures III GP, LLC | Former 10% Owner | Feb 12 '24 | Buy | 22.00 | 450,000 | 9,900,000 | 450,000 | Feb 12 05:51 PM | Bain Capital Life Sciences Inv | 10% Owner | Feb 12 '24 | Buy | 22.00 | 450,000 | 9,900,000 | 3,163,868 | Feb 14 05:26 PM | Vida Ventures, LLC | 10% Owner | Feb 12 '24 | Buy | 22.00 | 253,136 | 5,568,992 | 252,553 | Feb 14 07:04 PM |
|
|
|
|
Market Cap | 43.58M | EPS (ttm) | -0.06 |
P/E | - | EPS this Y | -237.50% |
Forward P/E | - | EPS next Y | 72.22% |
PEG | - | EPS past 5Y | - |
P/S | 3.13 | EPS next 5Y | - |
P/B | 5.02 | EPS Q/Q | -128.02% |
Dividend | - | Sales Q/Q | 119.62% |
Insider Own | 98.48% | Inst Own | 0.64% |
Insider Trans | 0.00% | Inst Trans | 11.29% |
Short Float | 3.07% | Earnings | Mar 21/b |
Analyst Recom | 1.00 | Target Price | 14.00 |
Avg Volume | 7.57K | 52W Range | 4.70 - 11.49 |
|
|
|
Interlink Electronics, Inc. engages in the design, development, manufacture, and sale of force sensing technology solutions. Its products include force sensing, position sensing and mouse pointing & touchpad. The company was founded on February 27, 1985 and is headquartered in Irvine, CA. |
|
| |
|
Market Cap | 18.99M | EPS (ttm) | -0.38 |
P/E | - | EPS this Y | - |
Forward P/E | - | EPS next Y | - |
PEG | - | EPS past 5Y | - |
P/S | - | EPS next 5Y | - |
P/B | - | EPS Q/Q | -16.75% |
Dividend | - | Sales Q/Q | - |
Insider Own | 53.21% | Inst Own | 5.81% |
Insider Trans | 0.00% | Inst Trans | 6.17% |
Short Float | 0.39% | Earnings | - |
Analyst Recom | - | Target Price | - |
Avg Volume | 1.12M | 52W Range | 1.30 - 12.80 |
|
|
|
CERo Therapeutics Holdings, Inc. is a blank check company, formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The company was founded on June 8, 2021 and is headquartered in Oakland, CA. |
|
|
|
Market Cap | 647.81M | EPS (ttm) | 0.88 |
P/E | 10.09 | EPS this Y | -22.01% |
Forward P/E | 6.05 | EPS next Y | 18.55% |
PEG | 0.40 | EPS past 5Y | 80.77% |
P/S | 0.37 | EPS next 5Y | 25.00% |
P/B | 1.03 | EPS Q/Q | -72.02% |
Dividend | - | Sales Q/Q | -12.11% |
Insider Own | 32.30% | Inst Own | 61.25% |
Insider Trans | -0.01% | Inst Trans | 1.29% |
Short Float | 4.83% | Earnings | May 01/a |
Analyst Recom | 3.00 | Target Price | 19.00 |
Avg Volume | 348.84K | 52W Range | 9.03 - 15.33 |
|
|
|
Titan International, Inc. is a holding company engaged in the manufacture of wheels, tires, and undercarriage industrial. It operates through the following segments: Agricultural, Earthmoving and Construction, and Consumer. The Agricultural segment manufactures rims, wheels, and tires for use in various agricultural and forestry equipment, including tractors, combines, skidders, plows, planters, and irrigation equipment. The Earthmoving and Construction segment produces rims, wheels, and tires for various types of off-the-road earthmoving, mining, military and construction equipment, including skid steers, aerial lifts, cranes, graders and levelers, scrapers, self-propelled shovel loaders, articulated dump trucks, load transporters, haul trucks, and backhoe loaders, crawler tractors, lattice cranes, shovels, and hydraulic excavators. The Consumer segment manufactures truck tires in Latin America and light truck tires in Russia and offers select products for turf and golf cart applications. The company was founded by John A. Stillwell in 1890 and is headquartered in West Chicago, IL. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Eheli Anthony | VP, Chief Accounting Officer | Mar 25 '24 | Sale | 12.42 | 2,500 | 31,050 | 52,918 | Mar 26 04:34 PM | Guinn Max A | Director | Sep 18 '23 | Sale | 12.49 | 18,402 | 229,841 | 132,379 | Sep 18 04:56 PM | Guinn Max A | Director | Sep 15 '23 | Sale | 12.60 | 1,598 | 20,135 | 150,781 | Sep 18 04:56 PM | Guinn Max A | Director | Sep 01 '23 | Sale | 12.97 | 29,650 | 384,560 | 152,379 | Sep 05 04:36 PM |
|
|
| |
|
Market Cap | 148.89M | EPS (ttm) | -1.61 |
P/E | - | EPS this Y | - |
Forward P/E | - | EPS next Y | - |
PEG | - | EPS past 5Y | 43.17% |
P/S | 6.34 | EPS next 5Y | - |
P/B | 0.34 | EPS Q/Q | -90.73% |
Dividend | - | Sales Q/Q | -64.19% |
Insider Own | 40.15% | Inst Own | 16.75% |
Insider Trans | 0.00% | Inst Trans | - |
Short Float | 0.09% | Earnings | - |
Analyst Recom | - | Target Price | - |
Avg Volume | 97.55K | 52W Range | 1.82 - 5.40 |
|
|
|
Osisko Development Corp. engages in the acquisition and exploration of mineral properties. It operates through the following projects. Cariboo, San Antonio, James Bay properties, Guerrero properties, and mineral reserve and resources. The company was founded on November 25, 2020 and is headquartered in Montreal, Canada. |
|
|
|
Market Cap | 10.68M | EPS (ttm) | -1.07 |
P/E | - | EPS this Y | - |
Forward P/E | - | EPS next Y | - |
PEG | - | EPS past 5Y | - |
P/S | 1.05 | EPS next 5Y | - |
P/B | - | EPS Q/Q | 12.46% |
Dividend | - | Sales Q/Q | -64.33% |
Insider Own | 70.26% | Inst Own | 10.84% |
Insider Trans | -0.68% | Inst Trans | -75.31% |
Short Float | 1.24% | Earnings | Apr 10/b |
Analyst Recom | 1.00 | Target Price | 10.00 |
Avg Volume | 1.66M | 52W Range | 0.18 - 2.55 |
|
|
|
Nauticus Robotics, Inc. engages in the development of ocean robots that are controlled through an AI-driven cloud software platform which enables a sliding scale spectrum of autonomous operations. It offers an aquanaut, hydronaut, argonaut, ToolKITT, and olympic arm. The company was founded by Nicolaus Adam Radford and Reginald Bruce Berka on November 24, 2021 and is headquartered in Webster, TX. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
FLORES WILLIAM | Director | Apr 15 '24 | Buy | 0.22 | 29,756 | 6,546 | 100,000 | Apr 15 05:11 PM | FLORES WILLIAM | Director | Apr 12 '24 | Buy | 0.23 | 70,244 | 16,156 | 70,244 | Apr 15 05:11 PM | GIBSON JOHN W JR | Interim CEO | Mar 13 '24 | Sale | 0.19 | 352,475 | 66,970 | 615,305 | Mar 15 07:56 PM | Radford Nicolaus | Chief Executive Officer | Jan 02 '24 | Sale | 0.64 | 19,667 | 12,587 | 3,024,921 | Jan 03 09:44 PM | Bohan Donnelly A. | Chief Operating Officer | Jan 02 '24 | Sale | 0.64 | 18,357 | 11,748 | 117,518 | Jan 03 09:44 PM |
|
|
|
|
Market Cap | 31.46M | EPS (ttm) | -2.15 |
P/E | - | EPS this Y | 595.59% |
Forward P/E | 2.71 | EPS next Y | 311.11% |
PEG | - | EPS past 5Y | -227.20% |
P/S | 0.28 | EPS next 5Y | 30.00% |
P/B | - | EPS Q/Q | -356.48% |
Dividend | - | Sales Q/Q | 112.47% |
Insider Own | 75.61% | Inst Own | 15.68% |
Insider Trans | -0.30% | Inst Trans | 157.88% |
Short Float | 24.98% | Earnings | Apr 15/b |
Analyst Recom | 1.67 | Target Price | 5.00 |
Avg Volume | 455.73K | 52W Range | 0.73 - 6.88 |
|
|
|
LuxUrban Hotels Inc. engages in the acquisition and management of hotel units. The company was founded on December 13, 2019 and is headquartered in Miami, FL. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Ferdinand Brian | Chairman & Co-CEO | Dec 13 '23 | Buy | 4.56 | 25,000 | 114,050 | 225,825 | Dec 14 08:30 AM | Ferdinand Brian | Chairman & Co-CEO | Dec 01 '23 | Sale | 4.45 | 14,219 | 63,275 | 15,347,917 | Dec 04 07:00 AM | Ferdinand Brian | Chairman & Co-CEO | Nov 30 '23 | Sale | 4.46 | 62,000 | 276,520 | 15,362,136 | Dec 04 07:00 AM | Ferdinand Brian | Chairman & Co-CEO | Nov 22 '23 | Sale | 5.21 | 6,556 | 34,157 | 15,424,136 | Nov 24 05:13 PM | Ferdinand Brian | Chairman & Co-CEO | Nov 21 '23 | Sale | 5.10 | 38,277 | 195,213 | 15,430,692 | Nov 24 05:13 PM |
|
|
|